{"id":"para-toluenesulfonamide","safety":{"commonSideEffects":[{"rate":"null","effect":"Hemolysis"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL574","moleculeType":"Small molecule","molecularWeight":"171.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Para-Toluenesulfonamide works by competitively inhibiting the enzyme dihydropteroate synthetase, which is necessary for the synthesis of tetrahydrofolate, a precursor to folic acid. This disruption prevents bacteria from producing folic acid, which is essential for DNA synthesis and cell division. As a result, bacterial growth is inhibited, and the infection is treated.","oneSentence":"Para-Toluenesulfonamide is a sulfonamide antibiotic that inhibits bacterial growth by disrupting folic acid synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:28.482Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Urinary tract infections"},{"name":"Pneumonia"}]},"trialDetails":[{"nctId":"NCT07332858","phase":"PHASE1, PHASE2","title":"First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion","status":"NOT_YET_RECRUITING","sponsor":"Gang Hou","startDate":"2026-01-20","conditions":"Malignant Pleural Effusions (Mpe), Non Small Cell Lung Cancer","enrollment":105},{"nctId":"NCT03447951","phase":"PHASE2","title":"A Study of PTS100 in Primary HCC Patients","status":"UNKNOWN","sponsor":"Gongwin Biopharm Co., Ltd.","startDate":"2018-06-19","conditions":"Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT03448211","phase":"PHASE1","title":"A Study of PTS for Patients With Solid Tumors","status":"WITHDRAWN","sponsor":"PTS International Inc.","startDate":"2018-05-01","conditions":"Solid Tumor","enrollment":""},{"nctId":"NCT03448146","phase":"PHASE3","title":"A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction","status":"COMPLETED","sponsor":"PTS International Inc.","startDate":"2009-08","conditions":"Nsclc","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PTS100","PTS"],"phase":"phase_3","status":"active","brandName":"Para-Toluenesulfonamide","genericName":"Para-Toluenesulfonamide","companyName":"Gongwin Biopharm Co., Ltd.","companyId":"gongwin-biopharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Para-Toluenesulfonamide is a sulfonamide antibiotic that inhibits bacterial growth by disrupting folic acid synthesis. Used for Urinary tract infections, Pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}